The assessment of expected performance is a function of near-, intermediate-, and long-term company fundamentals, industry outlook, confidence in earnings estimates, valuation (and our valuation methodology), and other factors. Individual ratings reflect the expected performance of the stock relative to the broader market (generally the S&P 500, unless otherwise indicated) over the next 12 months. uses a three-point system to rate stocks. Stock ratings and valuation methodologies: William Blair & Company, L.L.C. The compensation of the research analyst is based on a variety of factors, including the quality and accuracy of research, client feedback, contributions to other firm departments, competitive factors, and firm profitability. * Percentage of companies in each rating category that are investment banking clients, defined as companies for which William Blair has received compensation for investment banking services within the past 12 months. Please contact us at +1 8 or view disclosures on our coverage list.Īdditional information is available upon request.Ĭurrent Ratings Distribution (as of 10/20/21) Officers and employees of William Blair or its affiliates (other than research analysts) may have a financial interest in securities of Tempest Therapeutics, Inc. or an affiliate within the next three months. William Blair or an affiliate expects to receive or intends to seek compensation for investment banking services from Tempest Therapeutics, Inc. William Blair or an affiliate is a market maker in the security of Tempest Therapeutics, Inc. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments, or strategies to particular clients.
This report is not intended to provide personal investment advice. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. William Blair or an affiliate does and seeks to do business with companies covered in its research reports. *Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.
As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.* We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. William Blair is the premier global boutique with expertise in investment banking, investment management, and private wealth management. We believe the addition of TPST-1120 on top of standard of care in the first-line HCC setting provides a promising opportunity to jump straight to frontline treatment, although initial efficacy data is not expected until 2023.”
#Tempest therapeutics plus
Initial Phase I data showed a deep partial response in combination with Opdivo in a renal cell carcinoma patient previously treated with Opdivo plus Yervoy. He added, “Tempest is also trialing the first-in-clinic PPARα inhibitor TPST-1120 in a Phase I/Ib study as both monotherapy and in combination with Opdivo, as well as in a randomized Phase Ib/II study in first-line hepatocellular carcinoma (HCC) in collaboration with Roche.
Tempest is evaluating TPST-1495 in a monotherapy dose-finding study with plans to open a PD-1 combination study and expansion in specific cohorts, including PIK3CA-mutated tumors, in coming months.” “This provides strong rationale for evaluating TPST-1495, a dual antagonist of two key immuno-suppressive PGE2 receptors, EP2 and EP4, in these tumor types. “We believe there is compelling translational and clinical data showing PIK3CA-mutated tumors use PGE2-mediated immune suppression, and survival benefits have been seen across numerous clinical studies by blocking PGE2 production with NSAIDs, particularly in PIK3CA-mutated colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (SCCHN),” he said. (TPST $13.96), which is developing a pipeline of small-molecule therapies for novel disease targets, including TPST-1495, a dual EP2/EP4 antagonist, to treat prostaglandin-driven cancers.Īnalyst Matt Phipps noted the potential of Tempest’s pipeline of first-in-class targeted oncology programs, TPST-1495 and TPST-1120. William Blair initiated research coverage of Tempest Therapeutics, Inc.
0 kommentar(er)
